Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

MRTX849 Active in KRAS G12C+ NSCLC and CRC

October 29th 2019

The investigational KRAS G12C inhibitor MRTX849 demonstrated clinical activity in patients with non–small cell lung cancer and colorectal cancer.

Targeting Wnt in BRAF-Mutant Colorectal Cancer

October 28th 2019

Luke Dow, PhD, discusses phase I trials targeting the Wnt signaling pathway in colorectal cancer.

Addressing the Needs of Molecular Subgroups in CRC

October 28th 2019

Benjamin Weinberg, MD, discusses the treatment options available for the various subpopulations in metastatic colorectal cancer.

Dr. Corcoran on Immunotherapy for Microsatellite Stable/Instable CRC

October 26th 2019

Ryan B. Corcoran, MD, PhD, discusses immunotherapy options for patients with microsatellite stable versus microsatellite instability–high colorectal cancer.

Dr. Benson on Sequencing Strategies with Cetuximab in CRC

October 25th 2019

Al B. Benson, MD, discusses the optimal sequencing of the EGFR inhibitor cetuximab for patients with RAS wild-type colorectal cancer.

Pivotal Study Examines Blood Test as CRC Screening Method

October 24th 2019

In an effort to improve colorectal cancer screening rates via a less invasive method, the registrational ECLIPSE is evaluating the performance of the LUNAR-2 blood test in detecting colorectal cancer in average-risk adults.

Dr. Kasi on the Prognostic Value of ctDNA in CRC

October 24th 2019

Pashtoon M. Kasi, MD, MBBS, MS, discusses the prognostic value of circulating tumor DNA in colorectal cancer.

Dr. Bekaii-Saab on the Rationale to Explore Tucatinib/Trastuzumab in HER2-Overexpressing mCRC

October 23rd 2019

Tanios S. Bekaii-Saab, MD, FACP, discusses the rationale to explore the combination of tucatinib and trastuzumab (Herceptin) in patients with HER2-overexpressing metastatic colorectal cancer.

Dr. Benson on the Use of Genomic Testing in Newly Diagnosed mCRC

October 22nd 2019

Al B. Benson, MD, discusses the use of genomic testing in patients with newly diagnosed metastatic colorectal cancer.

Dr. Weinberg on Targeted Therapies for Molecular Subsets of mCRC

October 17th 2019

Benjamin Weinberg, MD, discusses treatment strategies for patients with different molecular subtypes of metastatic colorectal cancer.

Dr. Bekaii-Saab on the Addition of Atezolizumab to Capecitabine/Bevacizumab in MSS mCRC

October 15th 2019

Tanios S. Bekaii-Saab, MD, FACP, discusses the results of the phase II BACCI trial evaluating the addition of atezolizumab to capecitabine plus bevacizumab versus capecitabine/bevacizumab plus placebo in patients with microsatellite stable metastatic colorectal cancer.

Dr. Bekaii-Saab on Safety Profile of Tucatinib/Trastuzumab in HER2-Amplified mCRC

October 11th 2019

Tanios S. Bekaii-Saab, MD, discusses the safety profile of the combination of tucatinib and trastuzumab in patients with HER2-amplified metastatic colorectal cancer.

Next Steps for Immunoscore in Oncology

October 10th 2019

Jerome Galon, PhD, research director, French Institute of Health and Medical Research, discusses next steps with Immunoscore in oncology.

ATOMIC Looks at Immunotherapy in Early-Stage dMMR Colon Cancer

October 7th 2019

Investigators are seeking to determine whether immunotherapy that has been effective in metastatic colon cancers with deficient DNA mismatch repair can be applied to earlier-stage disease, specifically, nonmetastatic stage III colon cancer.

Dr. Bekaii-Saab on the Rationale to Evaluate Atezolizumab/Bevacizumab in MSS mCRC

October 5th 2019

Tanios S. Bekaii-Saab, MD, FACP, medical oncologist, medical director, Cancer Clinical Research Office, vice chair and section chief, Medical Oncology, Department of Internal Medicine, Mayo Clinic, discusses the rationale to evaluate atezolizumab (Tecentriq) and bevacizumab (Avastin) in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC).

Dr. Manji on Lack of Actionable Targets in Patients with Colorectal Cancer

October 2nd 2019

Gulam A. Manji, MD, PhD, discusses the importance of discovering other actionable targets for patients with colorectal cancer.

Dr. Messersmith on Choosing a Treatment Option in mCRC

September 26th 2019

Wells A. Messersmith, MD, discusses therapeutic options in metastatic colorectal cancer and what factors help determine the most appropriate option.

Dr. Lenz on Updated Results of the CheckMate-142 Trial in mCRC

September 25th 2019

Heinz-Josef Lenz, MD, FACP, discusses updated results from the phase II CheckMate-142 trial in metastatic colorectal cancer.

FDA Approves CRC Screening Test for Younger, At-Risk Individuals

September 23rd 2019

The FDA has expanded the approval of the noninvasive colorectal cancer (CRC) screening test Cologuard to include eligible at-risk individuals ≥45 years.

Top GI Oncologists Share Excitement on 16th Annual ISGIO Conference

September 20th 2019

Gastrointestinal oncology experts highlight what they are most excited for at the upcoming International Society of Gastrointestinal Oncology 16th Annual Gastrointestinal Oncology Conference.